Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003936 · ClinicalTrials.gov registry record · Phase 2
Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease
A Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003936 is a Phase 2 study that has completed, run by Barbara Ann Karmanos Cancer Institute.
The verdict
NCT00003936, a Phase 2 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have recurrent or refractory Hodgkin's disease.
Interventions
- DRUG bryostatin 1
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-06 |
| Est. Completion | 2004-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003936
The ClinicalTrials.gov registry entry for NCT00003936 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bryostatin 1 is the first listed.
NCT00003936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003936 about?
NCT00003936 is a clinical study titled "Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have recurrent or refractory Hodgkin's disease.
What is the current status of trial NCT00003936?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-06. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00003936?
The interventions under investigation include: bryostatin 1 (DRUG).
Who is sponsoring clinical trial NCT00003936?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.